A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases

Cited by papers we hold 11

• Metabolic reprogramming and epigenetic modifications on the path to cancer · 2021
  No notice
• Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability · 2020
  No notice
• The timeline of epigenetic drug discovery: from reality to dreams · 2019
  No notice
• Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials · 2019
  No notice
• Zinc binding groups for histone deacetylase inhibitors · 2018
  No notice
• Structural Basis for the Inhibition of Histone Deacetylase 8 (HDAC8), a Key Epigenetic Player in the Blood Fluke Schistosoma mansoni · 2013
  No notice
• SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease · 2011
  No notice
• Valproate Administered after Traumatic Brain Injury Provides Neuroprotection and Improves Cognitive Function in Rats · 2010
  No notice
• HMBA Releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and Activates HIV Transcription · 2007
  No notice
• Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth · 2001
  Not checked
• P21-dependent G1arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 · 2000
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.